ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  Related Studies  
Long Term Safety Of GW685698X Via Nasal Biopsy

This study has been completed.

Sponsored by: GlaxoSmithKline
Information provided by: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT00224523
  Purpose

Long term safety (52 weeks) of GW685698X on the nasal mucosa via nasal biopsy with an active control group (Nasonex®) and a healthy volunteers control group in subjects 18 years old with perennial allergic rhinitis . Allergic rhinitis is an inflammatory disorder of the upper airway that occurs following allergen exposure. Perennial allergic rhinitis is triggered by house dust mites, animal dander, etc., possibly causing symptoms year-round including nasal congestion, rhinorrhea and/or nasal itching.


Condition Intervention Phase
Perennial Allergic Rhinitis
Drug: GW685698X
Drug: mometasone furoate
Phase III

ChemIDplus related topics:   Mometasone furoate    Salicylsalicylic acid    Sodium salicylate   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety Study
Official Title:   A Randomized, Open Label, Active Controlled (Mometasone Furoate Aqueous Nasal Spray [Nasonex®] 200mcg QD), Parallel Group, Multi-Center, 52-Week Study to Assess the Long Term Safety of GW685698X Aqueous Nasal Spray 100mcg QD Via Nasal Biopsy in Subjects >18 Years of Age With Perennial Allergic Rhinitis (PAR)

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Quantitative and qualitative differences in the morphology and cytology of the nasal mucosa after 1 year of treatment.

Secondary Outcome Measures:
  • No Secondary Outcome Measures

Estimated Enrollment:   125
Study Start Date:   September 2005

  Eligibility
Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Criteria

Inclusion criteria:

  • History of perennial allergic rhinitis of 2 years, with a documented positive allergen test to an appropriate allergen.
  • Female patients of child-bearing potential must be willing to consistently and correctly use an acceptable method of birth control.

Exclusion criteria:

  • Patients who require certain medications for their allergy.
  • Patients with serious medical problems.
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00224523

Locations
Belgium
GSK Clinical Trials Call Center    
      Leuven, Belgium, 3000
Netherlands
GSK Clinical Trials Call Center    
      Nijmegen, Netherlands, 6525EX
GSK Clinical Trials Call Center    
      Amsterdam, Netherlands, 1105AZ
GSK Clinical Trials Call Center    
      Den Haag, Netherlands, 2566MJ

Sponsors and Collaborators
GlaxoSmithKline

Investigators
Study Director:     GSK Clinical Trials, MD     GlaxoSmithKline    
  More Information

Study ID Numbers:   FFR104503
First Received:   August 26, 2005
Last Updated:   August 22, 2007
ClinicalTrials.gov Identifier:   NCT00224523
Health Authority:   Belgium: The Federal Public Service (FPS) Health, Food Chain Safety and Environment

Keywords provided by GlaxoSmithKline:
GW685698X  
perennial allergic rhinitis  
nasal biopsy  

Study placed in the following topic categories:
Hypersensitivity
Otorhinolaryngologic Diseases
Respiratory Tract Infections
Respiratory Tract Diseases
Rhinitis, Allergic, Perennial
Mometasone furoate
Salicylsalicylic acid
Sodium Salicylate
Hypersensitivity, Immediate
Rhinitis
Respiratory Hypersensitivity

Additional relevant MeSH terms:
Anti-Inflammatory Agents
Immune System Diseases
Therapeutic Uses
Anti-Allergic Agents
Pharmacologic Actions
Nose Diseases

ClinicalTrials.gov processed this record on August 28, 2008




Links to all studies - primarily for crawlers